Biofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
Rhea-AI Summary
Biofrontera (NASDAQ:BFRI) reported record Q4 2025 revenue of $17.1M (+36% YoY) and a Q4 gross margin of 82.4% versus 58.0% a year earlier. The company posted Q4 net income of $5.6M, cash of $6.4M, and full‑year 2025 revenue of $41.7M.
Key operational moves include purchase of U.S. Ameluz and RhodoLED assets with a reduced earnout (12%–15%), FDA filing acceptance for an sNDA with a PDUFA in September 2026, positive acne and AK trial results, and the Xepi divestiture.
Positive
- Q4 revenue +36% YoY to $17.1M
- Q4 gross margin improved to 82.4% (≈2400 bps)
- Q4 net income of $5.6M (turned profitable)
- Earnout reduced to 12%–15%, lowering U.S. COGS exposure
- FDA filing acceptance for sNDA with PDUFA Sept 2026
Negative
- Full‑year net loss of $10.5M for 2025
- Adjusted EBITDA negative $(10.6)M for 2025
- Year‑end cash balance of $6.4M may pressure near‑term liquidity
News Market Reaction – BFRI
On the day this news was published, BFRI declined 1.50%, reflecting a mild negative market reaction. Argus tracked a peak move of +5.8% during that session. Argus tracked a trough of -14.0% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $170K from the company's valuation, bringing the market cap to $11M at that time. Trading volume was very high at 3.6x the daily average, suggesting heavy selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
BFRI was down 2.36% pre-release while peers were mixed: SNOA up 2.92%, IMCC up 2.87%, SBFM down 4.3%, YCBD down 2.6%. With gains and losses across names, moves appear stock-specific rather than a coordinated sector trend.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 13 | Q3 2025 earnings | Negative | -8.6% | Lower Q3 2025 revenues versus 2024 despite strategic deal and financing. |
| Aug 13 | Q2 2025 earnings | Positive | +1.7% | Strong Q2 revenue growth, higher H1 2025 sales and major restructuring. |
| May 15 | Q1 2025 earnings | Positive | -7.2% | Higher Q1 revenues and narrower net loss with pipeline progress. |
| Mar 21 | FY 2024 results | Positive | -16.5% | Record 2024 revenues and lower expenses but continued net loss. |
| Nov 13 | Q3 2024 earnings | Positive | -15.4% | Revenue growth and strong clinical data alongside ongoing operating losses. |
Earnings releases often highlighted revenue growth and strategic progress but were frequently followed by negative price reactions, indicating a history of the stock selling off around results despite generally constructive updates.
Over the past year, Biofrontera’s earnings news has focused on building the Ameluz/RhodoLED franchise and restructuring its economics. Events on May 15, 2025, Aug 13, 2025 and Nov 13, 2025 emphasized revenue growth, asset acquisitions, and new royalty terms. The Mar 21, 2025 update reported record 2024 revenues. Despite these milestones, several earnings days saw double‑digit percentage declines, showing that historically, solid operational progress did not always translate into positive near-term price reactions.
Historical Comparison
Past earnings releases led to an average move of -9.19%. This report continues themes of revenue growth, margin improvement and restructuring seen in prior quarters, against a backdrop of historically cautious market reactions.
Earnings updates since late 2024 show a progression from record 2024 revenues to restructuring Ameluz/RhodoLED economics in 2025, improving margins and narrowing losses through 2025 quarters. The current release extends this trajectory with record Q4 2025 and full-year 2025 results and a shift to quarterly profitability.
Market Pulse Summary
This announcement highlights record Q4 2025 revenue of $17.1 million, full-year 2025 revenue of $41.7 million and a sharp gross margin increase to 82.4% in the quarter and 73.7% for the year. The company turned Q4 operating income positive at $4.6 million while narrowing the annual net loss to $10.5 million. Alongside clinical progress in acne, sBCC and AK, investors may focus on whether this new cost structure and Q4 profitability can be maintained given the $6.4 million cash balance.
Key Terms
photodynamic therapy medical
pdt medical
phase 2b medical
phase 3 medical
supplemental new drug application regulatory
snda regulatory
adjusted ebitda financial
pharmacokinetics medical
AI-generated analysis. Not financial advice.
Conference call will be held today, Thursday, March 19 at 10:00 am ET
Woburn, MA, March 19, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported financial results for the three and twelve months ended December 31, 2025 and provided a business update.
Fourth Quarter Financial Highlights
- Revenues for 4Q25 were a record
$17.1 million , a36% increase compared to$12.6 million for the same period in 2024. - Gross margins were
82.4% , a roughly 2,400 basis point year over year increase compared to58.0% in 4Q24, reflecting the transition away from the transfer pricing model under the prior license and supply agreement. - Operating income was
$4.6 million in 4Q25 compared to a loss of$1.7 million in 4Q24. - Cash balance was
$6.4 million as of December 31, 2025.
Recent Operational Highlights
- Announced positive results of its Phase 2b clinical trial evaluating Ameluz® topical gel,
10% used in combination with the RhodoLED® red-light lamp series for the treatment of moderate to severe acne vulgaris (AV). - Announced FDA’s completion of its filing review and filing acceptance of the Company’s supplemental New Drug Application (sNDA) for Ameluz® Photodynamic Therapy (PDT) for the treatment of superficial basal cell carcinoma (sBCC).
- Announced positive and statistically significant top-line results from its Phase 3 clinical trial evaluating Ameluz® PDT with the red-light LED (RhodoLED®) platform for the treatment of mild to moderate actinic keratoses (AKs) on the extremities, neck, and trunk.
- Announced database lock of Phase 1 pharmacokinetics study required for FDA filing on treatment field on extremities, neck and trunk of up to 240 cm2.
- Closed the purchase of all Ameluz and RhodoLED US Assets from Biofrontera AG. New earnout structure reduces payment rate from
25% –35% to12% –15% of U.S. net sales. - Received the final
$2.5 million of$11 million financing led by existing investors in October. - In November, announced the divestiture of its Xepi antibiotic cream to Pelthos Pharmaceuticals for
$3 million at closing,$1 million upon commercial availability, and up to$6 million in milestone payments tied to revenue thresholds of$10 million and$15 million .
Hermann Luebbert, Chief Executive Officer and Chairman of Biofrontera Inc., stated: "2025 was a transformational year for Biofrontera. We delivered record annual and fourth quarter revenues, clear evidence that our refined commercial strategy is gaining traction and that the Ameluz PDT platform continues to resonate with dermatologists and their patients.
The completion of our strategic transaction with Biofrontera AG marks a fundamental inflection point for the Company. With full ownership and control of our U.S. assets—including intellectual property, regulatory approvals, and manufacturing rights—combined with a more favorable earnout structure, we have materially strengthened our cost profile. We saw this already in Q4 and expect the full annualized benefits of this transformation to be realized in 2026.
At the same time, our clinical pipeline is advancing with strong momentum, highlighted by a PDUFA date for sBCC in September 2026, positive Phase 3 results in AK on the extremities, and encouraging Phase 2b data in acne. With additional planned studies and patent protection extending through 2043, we believe we are uniquely positioned as the only company in the U.S. actively advancing FDA-controlled PDT clinical programs in dermatology.
Importantly, the combination of accelerating revenue growth, structurally lower cost of goods, and disciplined expense management drove profitability in the fourth quarter—the first full quarter reflecting our new cost structure. We believe this marks the beginning of a meaningful shift in our financial trajectory as we move toward sustained profitability and cash flow breakeven in 2026.”
Fourth Quarter Financial Results
Total revenues for the fourth quarter of 2025 were a record
Gross profit margin in the fourth quarter of 2025 was
Total operating expenses were
Selling, general and administrative expenses were
Net income for the fourth quarter of 2025 was
Adjusted EBITDA for the fourth quarter of 2025 was
Please refer to the table below which presents a GAAP to non-GAAP reconciliation of Adjusted EBITDA for the fourth quarters of 2025 and 2024.
Full Year 2025 Financial Results
Total revenues for full year 2025 increased
Gross profit margin for the full year 2025 was
Total operating expenses were
Net loss for the full year 2025 was
Adjusted EBITDA was
Conference Call Details
Conference call: Thursday, March 19, 2026 at 10:00 AM ET
Toll Free: 1-888-222-5806 (U.S. toll-free) International: 1-412-902-6516
Webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=XTq1cPRZ
About Biofrontera Inc.
Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with photodynamic therapy (PDT). The Company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, and in development for additional indications. For more information, visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and Twitter.
Contacts Investor Relations
Ben Shamsian
Lytham Partners
646-829-9701
shamsian@lythampartners.com
Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, in this press release, including statements regarding our strategy, future operations, regulatory process, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. The words “believe”, “anticipate”, “intend”, “expect”, “target”, “goal”, “estimate”, “plan”, “assume”, “may”, “will”, “predict”, “project”, “would”, “could” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. You should read this press release and any documents referenced herein completely and with the understanding that our actual future results may be materially different from what we expect. While we have based these forward-looking statements on our current expectations and projections about future events, we may not actually achieve the plans, intentions or expectations disclosed in or implied by our forward-looking statements, and you should not place undue reliance on our forward-looking statements.
These forward-looking statements are subject to risks, uncertainties and assumptions about us and accordingly, actual results or events could differ materially from the plans, intentions and expectations disclosed in or implied by the forward-looking statements we make. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: our ability to achieve and sustain profitability; our ability to compete effectively in selling our products; our ability to expand, manage and maintain our direct sales and marketing efforts, including our ability to obtain the financing to develop our marketing strategy, if needed; changes in our relationship with our manufacturing partners and the possible impact of tariffs; our ability to manufacture our products; our ability to adequately protect our intellectual property and operate the business without infringing upon the intellectual property rights of others; our actual financial results may vary significantly from forecasts and from period to period; our estimates regarding anticipated operating losses, future revenues, capital requirements and our needs for additional financing; market risks regarding consolidation and group purchasing organizations (“GPOs”) in the healthcare industry; the willingness of healthcare providers to purchase our products if coverage, reimbursement and pricing from third-party payors for our products, or procedures using our products significantly declines; our ability to market, commercialize, achieve market acceptance for and sell our products; the fact that product quality issues or product defects may harm our business; any claims brough against the Company, including but not limited to product liability claims, claims of patent infringement, or claims challenging the validity of our intellectual property; our ability to maintain compliance with The Nasdaq Stock Market, LLC (“Nasdaq”) continued listing standards; our ability to comply with the requirements of being a public company; the progress, timing and completion of research, development and preclinical studies and clinical trials for our products; our ability to obtain and maintain the regulatory approvals necessary for the marketing of our products in the United States, and; and other factors that may be disclosed in the Company's filings with the Securities and Exchange Commission ("SEC"), which can be obtained on the SEC website at www.sec.gov. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we may make. We do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Any forward-looking statements speak only as of the date on which they are made, and we undertake no obligation to publicly update or revise any forward-looking statements to reflect events or circumstances that may arise after the date of this press release, except as required by applicable law. Investors should evaluate any statements made by us in light of these important factors.
(Tables follow)
BIOFRONTERA INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except par value and share amounts)
| December 31, | ||||||||
| 2025 | 2024 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 6,392 | $ | 5,905 | ||||
| Investment, related party | 9 | 7 | ||||||
| Accounts receivable, net | 7,291 | 5,315 | ||||||
| Inventories | 1,426 | 6,646 | ||||||
| Prepaid expenses and other current assets | 2,279 | 527 | ||||||
| Asset held for sale | - | 2,300 | ||||||
| Other assets, related party | 686 | - | ||||||
| Total current assets | 18,083 | 20,700 | ||||||
| Inventories, long term | 3,729 | - | ||||||
| Property and equipment, net | 2,158 | 80 | ||||||
| Operating lease right-of-use assets | 1,584 | 903 | ||||||
| Intangible assets, net | 2,650 | 35 | ||||||
| Other assets | 360 | 383 | ||||||
| Total assets | $ | 28,564 | $ | 22,101 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | 1,855 | 1,856 | ||||||
| Accounts payable, related parties, net | 4,811 | 5,344 | ||||||
| Operating lease liabilities | 332 | 548 | ||||||
| Accrued expenses and other current liabilities | 4,897 | 4,273 | ||||||
| Total current liabilities | 11,895 | 12,021 | ||||||
| Long-term liabilities: | ||||||||
| Convertible notes payable | 4,589 | 4,098 | ||||||
| Warrant liabilities | 351 | 1,250 | ||||||
| Operating lease liabilities, non-current | 1,240 | 276 | ||||||
| Other liabilities | 9 | 23 | ||||||
| Total liabilities | 18,084 | 17,668 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders’ equity: | ||||||||
| Convertible Preferred Stock, | - | - | ||||||
| Common Stock, | 12 | 9 | ||||||
| Additional paid-in capital | 138,413 | 121,833 | ||||||
| Accumulated deficit | (127,945 | ) | (117,409 | ) | ||||
| Total stockholders’ equity | 10,480 | 4,433 | ||||||
| Total liabilities and stockholders’ equity | $ | 28,564 | $ | 22,101 | ||||
BIOFRONTERA INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts and number of shares)
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Product revenues, net | $ | 17,100 | $ | 12,560 | $ | 41,705 | $ | 37,303 | ||||||||
| Revenues, related party | - | - | - | 18 | ||||||||||||
| Total revenues, net | 17,100 | 12,560 | 41,705 | 37,321 | ||||||||||||
| Operating expenses | ||||||||||||||||
| Cost of revenues, related party | 2,734 | 5,016 | 10,111 | 17,855 | ||||||||||||
| Cost of revenues, other | 275 | 256 | 853 | 752 | ||||||||||||
| Selling, general and administrative | 8,523 | 8,192 | 37,751 | 33,793 | ||||||||||||
| Selling, general and administrative, related party | 223 | 12 | 619 | 42 | ||||||||||||
| Research and development | 787 | 796 | 3,719 | 2,089 | ||||||||||||
| Total operating expenses | 12,542 | 14,272 | 53,053 | 54,531 | ||||||||||||
| Income (Loss) from operations | 4,558 | (1,712 | ) | (11,348 | ) | (17,210 | ) | |||||||||
| Other income (expense) | ||||||||||||||||
| Change in fair value of warrant liabilities | 482 | 351 | 899 | 1,680 | ||||||||||||
| Change in fair value of investment, related party | (1 | ) | (1 | ) | 2 | (14 | ) | |||||||||
| Loss on debt extinguishment | - | - | - | (316 | ) | |||||||||||
| Interest expense, net | (120 | ) | (40 | ) | (452 | ) | (2,035 | ) | ||||||||
| Other income (expense), net | 721 | 4 | 388 | 158 | ||||||||||||
| Total other income (expense) | 1,082 | 314 | 837 | (527 | ) | |||||||||||
| Income (loss) before income taxes | 5,640 | (1,398 | ) | (10,511 | ) | (17,737 | ) | |||||||||
| Income tax expense | - | (2 | ) | 25 | 22 | |||||||||||
| Net income (loss) | $ | 5,640 | $ | (1,396 | ) | $ | (10,536 | ) | $ | (17,759 | ) | |||||
BIOFRONTERA INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In Thousands)
| Years ended December 31, | ||||||||
| 2025 | 2024 | |||||||
| Cash flows from operating activities: | ||||||||
| Net loss | $ | (10,536 | ) | $ | (17,759 | ) | ||
| Adjustments to reconcile net loss to cash flows used in operations | ||||||||
| Depreciation and amortization | 138 | 421 | ||||||
| Reduction in the carrying amount of right-of-use assets | 730 | 728 | ||||||
| Stock-based compensation | 951 | 1,019 | ||||||
| Non-cash interest expense | 491 | 297 | ||||||
| Allowance for credit losses | (69 | ) | 162 | |||||
| Change in fair value of warrant liabilities | (899 | ) | (1,680 | ) | ||||
| Gain on sale of asset held for sale | (700 | ) | - | |||||
| Loss from termination of operating leases | 19 | - | ||||||
| Realized/unrealized loss in investment, related party | (2 | ) | 14 | |||||
| Loss on debt extinguishment | - | 316 | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | (1,907 | ) | (315 | ) | ||||
| Other receivables, related party | - | 2 | ||||||
| Prepaid expenses and other assets | (1,728 | ) | (141 | ) | ||||
| Other assets, related party | (686 | ) | 5,159 | |||||
| Inventories | 1,445 | 4,233 | ||||||
| Accounts payable | (2 | ) | (1,452 | ) | ||||
| Accounts payable, related parties, net | (533 | ) | (355 | ) | ||||
| Operating lease liabilities | (683 | ) | (689 | ) | ||||
| Accrued expenses and other liabilities | 610 | (230 | ) | |||||
| Cash flows used in operating activities | (13,361 | ) | (10,270 | ) | ||||
| Cash flows from investing activities | ||||||||
| Proceeds from sale of asset held for sale | 3,000 | - | ||||||
| Sales of investment, related party | - | 57 | ||||||
| Purchase of intangible assets | - | (50 | ) | |||||
| Purchases of property and equipment | (2 | ) | (10 | ) | ||||
| Cash flows provided by (used in) investing activities | 2,998 | (3 | ) | |||||
| Cash flows from financing activities | ||||||||
| Proceeds from issuance of Series C preferred stock, net of offering costs | 10,850 | - | ||||||
| Proceeds from issuance of Series B-1 preferred stock and warrants to purchase series B-3 preferred stock, net of issuance costs | - | 7,662 | ||||||
| Proceeds from issuance of Series B-3 preferred stock from exercise of warrants | - | 7,438 | ||||||
| Proceeds from issuance of convertible notes, net of issuance costs | 4,050 | |||||||
| Payment of principal short-term debt | - | (4,315 | ) | |||||
| Cash flows provided by financing activities | 10,850 | 14,835 | ||||||
| Net increase in cash and cash equivalents | 487 | 4,562 | ||||||
| Cash, cash equivalents and restricted cash, at the beginning of the year | 6,105 | 1,543 | ||||||
| Cash, cash equivalents and restricted cash, at the end of the year | $ | 6,592 | $ | 6,105 | ||||
| Supplemental disclosure of cash flow information | ||||||||
| Interest paid | $ | 6 | $ | 1,728 | ||||
| Income tax paid, net | $ | 25 | $ | 24 | ||||
| Supplemental non-cash investing and financing activities | ||||||||
| Preferred stock issued as consideration in asset purchase acquisition (See Note 3. Asset Acquisition) | $ | 4,782 | $ | - | ||||
| Property, plant and equipment acquired | 2,126 | - | ||||||
| Intangible asset acquired | 2,656 | - | ||||||
| Addition of right-of-use assets in exchange for operating lease liabilities | $ | 1,371 | $ | 55 | ||||
BIOFRONTERA INC.
GAAP TO NON-GAAP ADJUSTED EBITDA RECONCILIATION
(In thousands, except per share amounts and number of shares)
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Net income (loss) | $ | 5,640 | $ | (1,396 | ) | $ | (10,536 | ) | $ | (17,759 | ) | |||||
| Interest expense, net | 121 | 40 | 452 | 2,035 | ||||||||||||
| Income tax expense | - | (3 | ) | 25 | 22 | |||||||||||
| Depreciation and amortization | 62 | 34 | 138 | 421 | ||||||||||||
| EBITDA | 5,823 | (1,325 | ) | (9,921 | ) | (15,281 | ) | |||||||||
| Gain on sale of asset held for sale | (700 | ) | - | (700 | ) | - | ||||||||||
| Change in fair value of warrant liabilities | (482 | ) | (351 | ) | (899 | ) | (1,680 | ) | ||||||||
| Change in fair value of investment, related party | 1 | 2 | (2 | ) | 14 | |||||||||||
| Loss on debt extinguishment | - | - | - | 316 | ||||||||||||
| Stock based compensation | 289 | 299 | 951 | 1,019 | ||||||||||||
| Expensed issuance costs | - | - | - | 354 | ||||||||||||
| Adjusted EBITDA | $ | 4,931 | $ | (1,375 | ) | $ | (10,571 | ) | $ | (15,258 | ) | |||||
| Adjusted EBITDA margin | 28.8 | % | -10.9 | % | -25.4 | % | -40.9 | % | ||||||||
FAQ
What did Biofrontera (BFRI) report for Q4 2025 revenue and growth?
How did Biofrontera's gross margin and profitability change in Q4 2025 for BFRI?
What is the significance of Biofrontera's U.S. asset purchase and earnout change for BFRI?
What regulatory milestones did Biofrontera (BFRI) announce and when is the PDUFA date?
What were Biofrontera's full‑year 2025 financial results and cash position for BFRI?
How did clinical trial results affect Biofrontera's 2025 outlook for BFRI?
